ATM kinase signals DNA double strand breaks (DSB) to cell cycle arrest via p53 and DNA repair.
Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer

INTRODUCTION
DNA is constantly being damaged either from endogenous sources or environmental mutagens and carcinogens. DNA double strand breaks (DSBs) are particularly cytotoxic and cells mount a co-ordinated response of cell cycle arrest and DNA repair in response to these lesions (1) . The Ataxia Telangiectasia Mutated (ATM) kinase is a major coordinator of the DSB response and is the product of the ATM gene, which is defective in the disease Ataxia Telangeictasia (A-T) that is characterised by neurodegeneration, immunodeficiency, cancer pre-disposition and an extreme hypersensitivity to ionising radiation (IR) and other DSB-inducing agents (2) . In response to DSBs ATM initiates a cascade of phosphorylation events to induce cell cycle arrest via p53 and other checkpoint proteins (reviewed in 3), and promote DNA repair by both homologous recombination and non-homologous end joining (4, 5) .
Ionising radiation and topoisomerase poisons are important anticancer agents that induce DNA DSBs. It is estimated that 1 Gy of irradiation induces 1,000 single strand breaks (SSB) and 25-40 double strand DNA breaks per diploid cell (6) . Topoisomerase II poisons, by stabilising the topoisomerase II-DNA cleavable complex, cause persistent protein-associated DNA DSBs while topoisomerase I poisons stabilise the topoisomerase I-DNA cleavable complex to cause persistent single strand breaks that are converted to DSB at replication. A-T cells display defective p53 induction and loss of cell cycle arrest; however, lack of ATM also confers radiosensitivity in some p53-null mouse tissues suggesting the existence of a p53-independent ATM effector pathway (7) . ATM inhibition is therefore an attractive approach to anti-cancer chemoand radio-sensitisation (8) with potential benefits in both p53 functional and dysfunctional cancers.
The C-terminal domain of ATM contains the serine threonine kinase signature motif characteristic of the PI3K family (9) . The PI3 Kinase inhibitor LY294002 (Table 1 ) inhibits other members of the PI3 Kinase family (10) and we previously used scaffold hopping from LY294002 to develop KU55933 as a selective inhibitor of ATM ( Table 1 ) that enhanced the cytotoxicity of ionising radiation (IR) and topoisomerase II poisons in human tumour cell lines (11) . Further development identified KU-600019 as a more potent and selective ATM inhibitor that radiosensitised glioma cells (12) . However, neither compound has been evaluated in vivo. In the work presented here we probe the p53-dependency of this class of compound and describe the novel ATM inhibitor KU59403 (Table 1) , with increased potency and specificity against ATM, improved pharmacological properties and promising activity in animal models of human cancer.
Materials and Methods
Chemicals
The specific ATM inhibitors, KU55933 and KU59403, were kindly provided by KuDOS, Horsham, United Kingdom. Etoposide phosphate and irinotecan (CPT-11) were purchased from the National Health Service (UK). All other chemicals were purchased from Sigma (Poole, UK) unless stated otherwise. KU55933, KU59403, doxorubicin, camptothecin and etoposide were dissolved in dimethyl sulfoxide (DMSO) for in vitro evaluation as 10 mM stocks and stored at -20°C. All drugs were added to cells such that the final concentration of DMSO in culture media was 0.5% (v/v), and results were compared with controls incubated with 0.5% DMSO in media alone. Irinotecan (CPT-11, clinical grade, formulated in saline) and etoposide phosphate (etopophos, clinical grade, formulated in saline) were used in place of camptothecin and etoposide, respectively, for in vivo studies. KU55933 was administered at 10 mg/kg (the maximum administrable dose due to limited solubility) formulated in equimolar phosphoric acid, 5% (v/v) DMSO, 10% (w/v)encapsin pH 4 and KU59403, formulated in equimolar phosphoric acid (Analar, UK) in physiological saline pH 4. All drugs for in vivo evaluation were formulated on the day of the experiment.
Enzyme inhibition
The activity of KU59403 against ATM and other PI3K family members isolated from HeLa cells was determined as previously described (11)
Cell lines and culture
LoVo, HCT116 and SW620 (human colon cancer), and U2OS (human osteosarcoma) and MDA-MB-231 (human breast cancer) cells were purchased from the American Type Culture Collection (Manassas, USA). They were maintained at <30 passages from receipt using separate reagents for each cell line. HCT116 N7 cells (HCT-116 cells stably transfected with a plasmid containing HPV16 E6 cDNA such that p53 protein is degraded through the ubiquitin-proteasome pathway (13)) were a gift from M. D'Incalci (Milan). U2OS p53 DN expressing the p53-R248W dominant negative mutant p53 were prepared by transfection of U2OS:PG13-Luc cells (14) , and the failure to mount a p53 response to IR was confirmed in these cells (Supplementary Figure 1) .
All cells were cultured in RPMI 1640 media supplemented with 10% (v/v) fetal bovine serum, penicillin (50 µnits/ml), and streptomycin (50 units/ml) at 37 o C in an atmosphere of 5% CO 2 in air. Cells were confirmed to be free of mycoplasma contamination and LoVo, SW620, HCT116
and MDA-MB-231 were authenticated by STR profiling (LGC Standards, Teddington, UK 
Cytotoxicity and growth inhibition studies
We determined the effect of KU55933 and KU59403 on cellular survival following exposure to Xirradiation or the topoisomerase II poisons, etoposide and doxorubicin, and the topoisomerase I poison, camptothecin, (Supplementary Figure 2) by clonogenic assay as described previously (15) . Briefly, exponentially growing cells were exposed to the cytotoxic agent with or without KU55933 (10 μM) or KU59403 (1.0 μM) for 16 hours and survival was calculated by comparison to the appropriate control (0.5% DMSO or ATM inhibitor alone). The dose modification ratio (DMR) was calculated as the percentage surviving cells (compared to control) treated with the cytotoxic agent alone, divided by the percentage surviving cells treated with the cytotoxic agent and the ATM inhibitor.
KU55933 and KU59403 pharmacokinetic and tissue distribution studies
All in vivo experiments were reviewed and approved by the relevant institutional animal welfare committees and performed according to national law and published guidelines (16) . 
HPLC analysis of ATM inhibitors in plasma and tissue homogenates
KU55933 and KU59403 were extracted from plasma and tissue homogenates (50 µl) and analysed by HPLC as described previously (15) . Plasma samples were quantified using a standard curve, prepared in plasma that was linear over the range: 0.05-10 µg/ml (r 2 >0.9) with duplicate QA standards (at 0.1, 1 and 10 µg/ml). Tissue concentrations were calculated using the method of addition (17) to account for the efficiency of recovery and compensate for intersample variation.
Anti-tumour efficacy studies
CD-1 nude mice were implanted with SW620 or HCT116-N7 human cancer cell lines at 
Statistical Analysis
Data were analysed data using Graphpad Prism software (GraphPad Software, Inc. San Diego Ca USA). For the in vitro studies significant differences between the effect of cytotoxic 
Results
In vitro activity of KU59403 and p53 independence of chemo-and radio-sensitisation KU59403 is a novel ATM inhibitor developed from LY294002 (Table 1) , which is more potent against ATM than the previous lead KU55933 (IC 50 3 nM vs 13 nM), and has at least 1000 times greater specificity for ATM over other members of the PI3K family tested.
In contrast to the concentrations of 10 μM of KU55933 and 3 μM KU-600019 needed to induce in vitro chemo-and radio-sensitisation (11, 12) , KU59403 was an effective chemo-sensitiser at a concentration of 1 μM. At this concentration KU59403 inhibited ATM activity in SW620 cells by >50%, at the higher concentration of 10 μM KU55933 also substantially inhibited ATM activity (Supplementary figure 3). KU59403 alone was not significantly cytotoxic to LoVo or SW620 cells (88± 7% and 91± 6% survival, respectively) but it enhanced camptothecin cytotoxicity ( Figure   1A , Table 2 ) in both cell lines with greater enhancement being observed in the LoVo compared to the SW620 cells (7-fold; p=0.038 versus 4-fold; p=0.014 at 10 nM camptothecin). KU59403 also significantly enhanced the cytotoxicity of fixed concentrations of etoposide (0.1 and 1 µM) or doxorubicin (10 or 100 nM) in these cell lines, with greater enhancement of etoposide in SW620 cells and of doxorubicin in LoVo cells (Table 2 ). tumours, they could harbour other genotypic or phenotypic differences that might mask the effect of p53 status. For this reason we investigated whether chemo-and radio-sensitivity was enhanced by ATM inhibition in a p53-dependent manner using paired cell lines with functional or dysfunctional p53 using KU55933 as a model compound to confirm the data with KU59403 in proof of principle studies. KU55933 (10 μM) sensitised p53 functional and dysfunctional HCT116 and U2OS cells to camptothecin to a similar extent (4 to 5-fold, Fig 1B and Supplementary Table   1 ). Radiosensitisation by KU55933 was greater in HCT116 than in U20S cells but the p53 status did not affect radiosensitivity or enhancement by KU55933 (Fig 1C, Supplementary Table 1 ). The p53 status of the cell did not have a consistent effect on chemosensitisation of topoisomerase II poisons by KU55933 either, for example p53 dysfunction conferred reduced sensitisation to etoposide and doxorubicin in U20S cells but had no significant impact in HCT116 cells (Supplementary Table 2 ). Consistent with the p53 independence of chemo-and radiosensitisation, KU55933 increased the G2 cell cycle arrest induced by IR, camptothecin, doxorubicin and etoposide to a similar extent in p53 functional and dysfunctional cells and did not affect DNA DSB formation or repair kinetics (Supplementary Figures 4 and 5) . These data were confirmed with KU59403 (1 µM) which enhanced etoposide (1 µM) cytotoxicity to a similar extent in HCT116 and HCT116-N7cells by 2.3 ± 1.6-fold (p=0.011) and 3.8 ± 2.5-fold (p=0.019), respectively, and in the p53 mutant SW620 cells and human breast cancer cell line, MDA-MB-231, sensitisation was 11.9 ± 4.7 (p<0.0001) and 3. data, SW620 tumours treated with etoposide were chosen as our primary model system for the evaluation of KU59403 in in vivo studies.
Pharmacokinetics
As part of initial studies, plasma and tumour concentrations of drug were measured at 1 and 4 hours after administration of a single dose of KU59403 at 50 mg/kg i.p. and KU55933 at the maximum administrable dose of 10 mg/kg. The plasma concentration of KU59403 was 5 µM, and maintained for at least 4 hours. In comparison, plasma levels of KU55933 were just over 1 μM, consistent with the 5-fold lower dose administered (Figure 2A ). KU59403 accumulated in tumour tissue up to the 4 hour time point with a concentration at this time of 1.9 µM, which is greater than that shown to be necessary for activity in the in vitro studies (Figure 2A ). In contrast, the levels of KU55933 in the tumour were below the limit of detection (0.5 µM). To determine the pharmacokinetics of KU59403 in normal tissues, the compound was administered to female Balb/C mice at 25 mg/kg intravenously (i.v.) ( Figure 2B ). In contrast to the previous experiment, KU59403 was cleared rapidly from the plasma and at 4 hr the plasma concentration was less than 0.1 µM. This difference could be due to different route of administration, different dose or strain specific metabolism. There was, nevertheless, substantial accumulation and retention in the tissues, especially the liver, indicating that hepatic clearance may be the main route of elimination of this compound. At this dose and route of administration KU59403 achieved concentrations in tissues in excess of those required for in vitro chemo-sensitisation.
Antitumour efficacy studies.
To investigate whether the marked chemo-sensitisation by KU59403 observed in vitro could be reproduced in vivo we treated mice bearing SW620 tumour xenografts with etoposide phosphate (etopophos) at a fixed dose of 11.35 mg/kg (equivalent to 10 mg/kg free etoposide) Whitney test p=0.037). Toxicity, as measured by body weight loss, was tolerable and transient (Supplementary Figure 5B) .
Irinotecan, a member of the camptothecin group of compounds. is commonly used in the treatment of colon cancer. In this study irinotecan alone caused an initial modest regression of the SW620 tumour followed by rapid re-growth resulting in a tumour growth delay of 7.5 days, which was extended to 19.5 days by the co-administration of KU59403. This represents a 144% enhancement of irinotecan-induced tumour growth delay, which was significantly different from irinotecan alone (p=0.032) ( Figure 3C , Table 3 ). There were no unacceptable adverse effects on animal body weights at any of the doses given in this study (Supplementary Figure 5C) . As is clearly indicated from these data, enhancement of the efficacy of etopophos can be obtained in the SW620 and HCT116 xenograft models, and of irinotecan in the SW620 model, by combination with KU59403 with little enhancement of toxicity (measured by body weight loss).
Discussion
We had previously identified KU55933 as a potent and selective inhibitor of ATM (11), and subsequently KU-600019 has been identified as a more potent ATM inhibitor (12) Unfortunately, although these compounds provided in vitro evidence that inhibiting ATM induced chemo-and radio-sensitisation in tumour cell lines, to date there have been no in vivo investigations with small molecule ATM inhibitors. Here we described KU59403, a novel inhibitor of the ATM kinase that is more potent (IC 50 = 3 nM) and specific (at least 1000-fold selective for ATM compared with the other members of the PIKK family tested) than previously described compounds of this class. As well as improved potency over KU55933, KU59403 also exhibits improved solubility, Studies in matched p53 proficient and deficient cell lines showed that p53 status had no impact on chemo-sensitisation by KU59403 or KU55933, and p53 status was not a determinant of the effect of KU55933 on cell cycle arrest or DNA DSB repair. Cytotoxic drug or IR exposure resulted in G2 arrest in cells with both wild type and dysfunctional p53 suggesting that G1 checkpoints were compromised in these cells irrespective of p53 status (21) . The G2 arrest was enhanced by KU49403 independently of p53 status but whether this reflects further impairment of the G1 checkpoint, or that ATR signalling to the G2 checkpoint is increased when ATM is inhibited, remains to be determined. Since ATM signalling is proposed to be an early response to DNA DSB , these data confirm the need to inhibit ATM whilst DNA DSB are being induced.
We have also shown that KU59403 can be used to enhance the sensitivity of human colon cancer cell lines to topoisomerase I poisons both in vitro and in vivo. 
respectively), and gave a 144% enhancement of irinotecan efficacy in a SW620 human xenograft model. These data as a whole are very encouraging and support the further development of this class of compound.
In summary, our studies have shown that ATM is valid target for the development of drugs designed to improve the activity of certain cytotoxic anticancer therapies. KU59403 is a potent and selective inhibitor of ATM, which is without intrinsic cytotoxicity but is a potent enhancer of topoisomerase I and II poison cytotoxicity in vitro. We have demonstrated that KU59403, increases the efficacy of topoisomerase I and topoisomerase II poisons in vivo without intrinsic toxicity despite normal tissue exposure. These data provide further proof of principle evidence for the strategy of inhibiting ATM as a therapeutic manoeuvre for anticancer therapy. 
